Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname

Bihariesingh, Rosita; Bansie, Rakesh; Ramdhani, Navin; Mangroo, R; Bustamente, D; Diaz, E.; Foek, C. Fung A; Thakoer, I; Vreden, Stephen; Choudhry, Z; Wout, Angélique B. van 't; Diavatopoulos, Dimitri A.; Nierich, Arno P.

doi:10.1128/mbio.03379-22

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3.1. Collection, Validation and Characteristics of CCP CCP has generally been collected by single productive plasmapheresis, which is quite expensive and requires trained personnel, although whole blood donation and HemoClear ® procurement have also been reported in low-to-middle income countries [3]. In the initial phase of the pandemic, qualification was bound to viral neutralization tests to measure neutralizing antibody (nAb) titers, which are time-and money-consuming, lack standardization, and can only be run in biosafety level 3 facilities [4].…”

Section: Convalescent Plasma Against Covid-19mentioning

confidence: 99%

The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review

Franchini,

Focosi

2023

Life

View full text Add to dashboard Cite

COVID-19 convalescent plasma (CCP) has represented the frontline response to the COVID-19 pandemic, largely because of encouraging historical evidences in previous pandemics, biological plausibility, and the initial unavailability of targeted antivirals. Unfortunately, investigator-initiated randomized clinical trials in 2020, launched during a stressful pandemic peak, were designed mostly at addressing the main unmet need, i.e., treating critically ill hospitalized patients who were unlikely to benefit from any antiviral therapy. The failure of most of these drugs, in combination with the lack of any sponsor, led to the false belief that convalescent plasma was useless. With the relaxing pandemic stages, evidences have instead mounted that, when administered properly (i.e., within 5 days from onset of symptoms and at high titers of neutralizing antibodies), CCP is as effective as other antivirals at preventing disease progression in outpatients, and also reduces mortality in hospitalized patients. Recently, the focus of clinical use has been on immunosuppressed patients with persistent seronegativity and infection, where a randomized clinical trial has shown a reduction in mortality. Lessons learnt during the COVID-19 pandemic will be of utmost importance for future pandemics.

show abstract

Section: Convalescent Plasma Against Covid-19mentioning

confidence: 99%

The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review

Franchini,

Focosi

2023

Life

View full text Add to dashboard Cite

show abstract

“…Unfortunately, high upfront costs and technological barriers of conventional centrifugal plasmapheresis have limited the collection and processing of CCP in Low-and Middle-Income Countries (LMICs) (8). Previously, we have successfully used a novel gravity-driven crossflow blood filter to obtain CCP and treat ICU admitted patients in Suriname (9).…”

Section: Introductionmentioning

confidence: 99%

Gravity-driven crossflow membrane filtration and mechanical centrifugation yield plasma with equivalent total and COVID-19-specific immunoglobulin content

Rosita Bihariesingh-Sanchit,

Rakesh Bansie,

Shannon Tjon A Sam

et al. 2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

While the administration of convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), upfront costs and technological barriers of conventional plasmapheresis have limited the collection and processing of COVID-19 convalescent plasma (CCP) in Low- and Middle-Income Countries (LMICs). We previously reported that bedside plasma separation using gravity-driven microfiltration has made CCP therapy accessible as a treatment option in Suriname. However, the question remains whether the gravity-driven microfiltration method yields similar amounts of immunoglobulins as compared to conventional plasmapheresis. Here, we compared the gravity-driven microfiltration method with conventional plasma centrifugation for the total and COVID-19-specific immunoglobulin content of the obtained CCP. Blood donations from 10 donors recovered from PCR-confirmed COVID-19 were processed using both methods. Samples were collected pre- and post-processing for analysis to allow direct comparison of both methods. There were no differences in COVID-19-specific IgG levels between convalescent plasma obtained by microfiltration and centrifugation for 4 of the 5 assays used. Anti-RBD-Omicron IgG levels were slightly higher in the plasma obtained after filtration (median 274, range 69 to 1258) than after centrifugation (median 249, range 67 to 1175), Wilcoxon P = 0.0488. No significant differences were detected between the two methods for levels of total albumin, total cholesterol, total IgA, IgM and IgG levels. These results indicate that gravity-driven microfiltration and conventional centrifugation yield CCP with equivalent amounts of total and COVID-19-specific antibodies. This makes the gravity-driven microfiltration method a viable option for the collection and treatment with CCP in the LMICs setting.

show abstract